NCT02989974 (KYLEADS-SC) is a NA clinical trial of KY LEADS Survivorship Care in Lung Cancer, sponsored by Jamie Studts.

Who is sponsoring NCT02989974?

NCT02989974 is sponsored by Jamie Studts.

What drugs are being tested in NCT02989974?

Interventions in NCT02989974: KY LEADS Survivorship Care.

What condition does NCT02989974 study?

NCT02989974 studies Lung Cancer.

Is NCT02989974 still recruiting?

NCT02989974 is currently completed. Last updated 29 October 2020.

Last reviewed 2020-10-29 · How we verify

NCT02989974: KYLEADS-SC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kentucky LEADS Collaborative: Lung Cancer Survivorship Care Program

Completed NA Last updated 29 October 2020

What this trial tests

NA trial testing KY LEADS Survivorship Care in Lung Cancer in 214 participants. Completed in 24 April 2019.

Timeline

10 February 2017

Primary endpoint
24 April 2019

24 April 2019

Quick facts

Lead sponsor	Jamie Studts
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	214
Start date	10 February 2017
Primary completion	24 April 2019
Estimated completion	24 April 2019
Sites	9 locations across United States

Drugs / interventions tested

KY LEADS Survivorship Care

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Jamie Studts

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the Kentucky LEADS Lung Cancer Survivorship Care Program is to develop, administer and evaluate the impact of a comprehensive psychosocial survivorship care program for individuals diagnosed with lung cancer and their caregivers to improve lung cancer survivorship and delivery of high-quality lung cancer care. The investigators hypothesize that the Kentucky LEADS Lung Cancer Survivorship Care Program will demonstrate improved quality of life, better symptom control, increased tobacco treatment, and reduced distress among lung cancer survivors and their caregivers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02989974 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jamie Studts
Last refreshed: 29 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02989974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing